Percutaneous Mitral Annuloplasty: First Results with CARILLON Device

Findings from a feasibility study are promising but need to be confirmed in randomized trials.

Much interest surrounds the development of a percutaneous alternative to surgery for patients with functional mitral regurgitation (MR). In this manufacturer-sponsored, prospective, multicenter trial, investigators examined the safety of a fixed-length, double-anchor, nitinol coronary sinus device (CARILLON) used to plicate the periannular tissue. A total of 48 patients with NYHA class II–IV heart failure and moderate-to-severe MR were enrolled.

Devices were not implanted in 18 patients owing to insufficient MR reduction, device slippage, or complications including coronary sinus perforation (3 patients) and coronary artery compromise (6 patients). During 30-day follow-up, seven major adverse events occurred, including death (1 patient) and …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)